It is a meaningful leap forward in how we treat obesity pharmacologically
Patients with established cardiovascular disease or multiple risk factors should use ibuprofen cautiously and only when necessary
Schedule a consultation with our expert team to discuss your options
CrossRef c-FLIP as a master regulator of immune homeostasis and disease mechanisms Eliana Urbini, Annalisa Adamo, Yushu Hu, Luca Giacobazzi, Silvia Dusi, Francesco De Sanctis, Carmine Carbone, Davide Gibellini, Sara Pilotto, Vincenzo Corbo, Vincenzo Bronte, Fulvia Vascotto, Stefano Ugel Cell Death & Disease .2026;[Epub] CrossRef Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective Enrico Torre, Sergio Di Matteo, Chiara Martinotti, Giacomo Bruno, Alessandro Cabrino, Emma Fogliati, Andrea Giusti, Marco Barbieri, Luigi Bottaro, Giorgio Colombo ClinicoEconomics and Outcomes Research .2026